Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 3/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22024174 | 0.97 | CCR2 (0.33) | PDE4APDE4BPDE4CPDE4DMAOA | |
| SCHEMBL21884191 | 0.87 | CCR2 (0.34) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL22023873 | 0.83 | PDE4A (0.33) | PDE4APDE4BPDE4CPDE4DGAA | |
| SCHEMBL23634129 | 0.80 | CCR2 (0.36) | PDE4APDE4BPDE4CPDE4DMAOA | |
| SCHEMBL22024008 | 0.80 | CCR2 (0.36) | PDE4APDE4BPDE4CPDE4DMAOA | |
| SCHEMBL21191549 | 0.79 | PDE4A (0.34) | PDE4APDE4BPDE4CPDE4DGAA | |
| SCHEMBL22023911 | 0.78 | SLC2A1 (0.35) | PDE4AALDH1A1GAATSHR | |
| SCHEMBL14592820 | 0.73 | ALDH1A1 (0.34) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL8931418 | 0.73 | ALDH1A1 (0.34) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL14592897 | 0.73 | ALDH1A1 (0.34) | PDE4APDE4BPDE4CPDE4DALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | PDE4A 2385/4885PDE4B 2436/4885PDE4C 1871/4885 |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | PDE4A 2385/4885PDE4B 2436/4885PDE4C 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.